These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 18028171

  • 1. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T, Toya Y, Kawaguchi Y, Tamura K, Iwatsubo K, Dobashi Y, Nakazawa A, Takeda H, Iwatsubo M, Hirawa N, Yasuda G, Ohnishi T, Umemura S.
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [Abstract] [Full Text] [Related]

  • 2. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
    Inoue T, Nagatoya K, Kagitani M, Shibahara N, Ueda H, Katsuoka Y, Ohashi S, Kitagawa Y, Nishimoto K, Yasuda H, Hokusetsu Renal Osteodystrophy Study Group.
    Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
    [Abstract] [Full Text] [Related]

  • 3. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [Abstract] [Full Text] [Related]

  • 4. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM.
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [Abstract] [Full Text] [Related]

  • 5. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients.
    Lin YF, Chen YM, Hung KY, Chu TS, Kan WC, Huang CY, Lin SL, Kao TW, Huang JW, Chiang WC, Yen CJ, Tsai TJ, Wu KD, Wu MS.
    J Formos Med Assoc; 2010 Sep; 109(9):663-72. PubMed ID: 20863994
    [Abstract] [Full Text] [Related]

  • 6. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
    Hamano T, Oseto S, Fujii N, Ito T, Katayama M, Horio M, Imai E, Hori M.
    Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
    [Abstract] [Full Text] [Related]

  • 7. Secretion of parathyroid hormone oscillates depending on the change in serum ionized calcium during hemodialysis and may affect bone metabolism.
    Kitahara T, Ueki K, Kuroiwa T, Kaneko Y, Hiromura K, Nojima Y.
    Nephron Clin Pract; 2005 May; 101(1):c9-17. PubMed ID: 15886497
    [Abstract] [Full Text] [Related]

  • 8. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, Lin PW, Liu JH, Liao PY, Huang CC.
    Ren Fail; 2006 May; 28(8):701-7. PubMed ID: 17162430
    [Abstract] [Full Text] [Related]

  • 9. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
    Izumi M, Shirai K, Ito K, Miyamoto T, Matsumoto A, Takenaka Y, Nakagawa K, Yamanashi T, Takamitsu Y, Nakanish T.
    Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
    [Abstract] [Full Text] [Related]

  • 10. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
    Furukawa K, Ikawa T, Yokoi S, Yokouchi S, Kato K, Ueno M, Takahashi J.
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
    [Abstract] [Full Text] [Related]

  • 11. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L, He JX, Chen YY, Ling YS, Lin CH, Guan TJ.
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [Abstract] [Full Text] [Related]

  • 12. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG, Frangiosa A, Anastasio P, Marino A, Correale G, Perna A, Di Stazio E, Stellato D, Santoro D, Di Meglio E, Iacono G, Ciacci C, Savica V, Cirillo M.
    J Nephrol; 2006 Nov; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [Abstract] [Full Text] [Related]

  • 13. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Jüppner H.
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
    Wilkes BM, Reiner D, Kern M, Burke S.
    Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
    Suñer M, Guerrero A, Montes R, Rivera M, Ruiz A, Martínez-García M, Pérez-Valdivia MA, Mateos J.
    Nefrologia; 2004 Dec; 24(2):142-8. PubMed ID: 15219089
    [Abstract] [Full Text] [Related]

  • 16. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R, Dryja P, Łacina D, Króliczak V, Chrul S, Kacprzyk F.
    Wiad Lek; 2011 Dec; 64(1):9-14. PubMed ID: 21812357
    [Abstract] [Full Text] [Related]

  • 17. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis.
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [Abstract] [Full Text] [Related]

  • 18. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
    Nolan CR.
    Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
    [Abstract] [Full Text] [Related]

  • 19. Effects of vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels.
    Nakashima A, Yorioka N, Doi S, Masaki T, Ito T, Harada S.
    Bone; 2004 Mar; 34(3):579-83. PubMed ID: 15003806
    [Abstract] [Full Text] [Related]

  • 20. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
    Bielesz BO, Hecking M, Plischke M, Cejka D, Kieweg H, Haas M, Marculescu R, Hörl WH, Bieglmayer C, Sunder-Plassmann G.
    Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.